血液型タイピングの世界市場：2024～2031年

概要

血液型タイピングの世界市場は、2023年に20億8,000万米ドルに達し、2031年には41億4,000万米ドルに達し、予測期間2024-2031年にはCAGR9.2%で成長すると予測されています。

血液型タイピングは、輸血を受ける患者血液型を正確に一致させるため重要な医療サービスです。

現在、患者は日常的にABO血液型タイピングを受け、血液型がA、B、AB、O4つ主要型いずれかであるか、またRhDが陽性か陰性かを判定され、ほとんど患者はこれら一般的な血液型いずれかと正確に適合させることができます。

しかし、医学進歩により、現在では少なくとも43種類血液型が認識できるようになり、特にハイリスク患者にとっては、血液型タイピングでより正確な適合を得ることが重要です。

血液型タイピングは、伝統的な血清学的検査に基づいて、順型検査と逆型検査に分類することができます。具体的には、フォワード・タイピングは特異的抗血清による赤血球凝集と凝集強度に基づいてA抗原とB抗原を検出するに対し、リバース・タイピングは血漿または血清中抗A抗体、抗B抗体、抗AB抗体有無を識別するために用いられます。

市場力学

促進要因

輸血を必要とする交通事故、緊急事態、外傷事例の増加

世界の血液型タイピング市場の需要は複数の要因によって牽引されています。促進要因の1つは、輸血を必要とする交通事故、緊急事態、外傷事例の増加であり、血液型タイピング市場の重要な促進要因です。

交通事故や外傷の場合、重傷を負い、出血性ショックや慢性貧血に陥ることが多く、大手術が必要になることもあります。このような状況では、輸血は患者の生存を確保するために極めて重要です。

加えて、業界の主要企業が新たな発売や革新的なアプリを導入することは、この市場の成長を促進すると思われます。2024年6月のNational Blood Transfusion Committeeによると、Transfusionは新しいTransfusion Training Hubを導入し、輸血に携わるすべての医療従事者や輸血の知識を深めたい人のための教育訓練をサポートするよう特別に設計されました。

同様に2024年2月、NHS Blood and Transplant（NHSBT）は、救命輸血のための血液検査プロセスをリアルにシミュレートする、初の革新的なバーチャルリアリティトレーニングアプリ「NHSBT Blood Identification」をリリースしました。

さらに、パートナーシップやコラボレーションなどの主要プレーヤーの戦略は、この市場の成長を促進すると思われます。例えば、2023年3月、Werfen社はImmucor, Inc.の買収を完了し、特殊診断におけるリーダーシップを拡大しました。この提携により、ワーフェンは病院や臨床検査室向けの診断ソリューションのポートフォリオを拡大します。

血液型タイピング製品の高コスト、血液型タイピングの複雑さ、貧弱な血液サービスインフラ、認識と熟練した専門家の不足、厳しい規制、先端技術へのアクセスの制限などの製品タイプが市場の妨げになると予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 輸血を必要とする交通事故、緊急事態、外傷事例の増加
    • 出生前検査における血液型タイピング需要の増加
    • 献血数の増加
  • 抑制要因
    • 血液型タイピング製品の高コスト
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• アンメットニーズ
• PESTEL分析
• 特許分析
• SWOT分析

第6章 COVID-19分析

第7章 製品別

• 消耗品
• 器具
• サービス

第8章 技術別

• PCRベース技術
• アレル特異的PCR
• リアルタイムPCR
• アッセイベース技術
• マイクロアレイベース技術
• 超並列シーケンス

第9章 検査タイプ別

• ABO血液検査
• 抗原タイピング
• 抗体スクリーニング
• HLAタイピング
• クロスマッチング検査

第10章 エンドユーザー別

• 病院
• 外来手術センター
• 血液銀行
• 臨床検査室
• その他

第11章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第12章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第13章 企業プロファイル

• Bio-Rad Laboratories, Inc
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Grifols
• Thermo Fisher Scientific Inc
• Agena Bioscience, Inc
• Bag Diagnostics
• Lorne Laboratories Limited
• Tulip Diagnostics
• DIALAB GmbH
• Rapid Labs Limited
• Immucor, Inc

第14章 付録

Overview

The global blood group typing market reached US$ 2.08 billion in 2023 and is expected to reach US$ 4.14 billion by 2031, growing at a CAGR of 9.2% during the forecast period 2024-2031.

Blood typing is an important medical service that is used to ensure that patients who are given a transfusion are matched accurately with their blood type.

Currently, patients are routinely tested for ABO blood type to determine if their blood is one of four main types - A, B, AB, or O - and either RhD positive or negative and most patients can be accurately matched with one of these common blood types.

But because of advances in medical science, we now can recognize at least 43 different blood group systems, and it's important, especially for high-risk patients, that blood typing provides a more precise match.

Blood group typing can be classified as forward and reverse typing based on traditional serological testing. Specifically, forward typing involves the detection of A and B antigens based on RBC agglutination by the specific antiserum and the intensity of agglutination, whereas reverse typing is used to identify the presence or absence of anti-A, anti-B, and anti-AB antibodies in plasma or serum.

Market Dynamics

Drivers

Increasing Number of Road Accidents, Emergencies, & Trauma Cases Necessitating Blood Transfusions

The demand for the global blood group typing market is driven by multiple factors. One of the driving factors is the increasing number of road accidents, emergencies, and trauma cases requiring blood transfusions is a significant driver of the blood group typing market.

Road accidents and trauma cases often result in severe injuries, hemorrhagic shock, and chronic anemia, which may require major surgeries. In such situations, blood transfusions are crucial to ensure the patient's survival.

In addition, key players in the industry introducing new launches and innovative apps would drive this market growth. According to the National Blood Transfusion Committee in June 2024, Transfusion introduced the new Transfusion Training Hub, specifically designed to support education and training for all healthcare professionals working with Blood Transfusion and for anyone wishing to increase their transfusion knowledge.

Similarly in February 2024, NHS Blood and Transplant (NHSBT) released its' first innovative virtual reality training app 'NHSBT Blood Identification' which realistically simulates the process of testing blood for lifesaving blood transfusions.

Moreover, key players strategies such as partnerships and collaborations would drive this market growth. For instance, in March 2023, Werfen completed the acquisition of Immucor, Inc., expanding leadership in Specialized Diagnostics. By using this partnership, Werfen expands its portfolio of diagnostic solutions for hospitals and clinical laboratories.

Factors such as the high cost of blood group typing products, the complexity of blood group typing, poor blood services infrastructure, lack of awareness & skilled professionals, stringent regulations, and limited access to advanced technology are expected to hamper the market.

For more details on this report - Request for Sample

Segment Analysis

The global blood group typing market is segmented based on product, technique, test type, end-user, and region.

The ABO blood tests segment accounted for approximately 23.4% of the global blood group typing market share

The ABO blood tests segment is expected to hold the largest market share over the forecast period. The ABO system is defined by the presence or absence of the A and/or B antigens on human red blood cells and by the presence of antibodies in the plasma or serum corresponding to the antigen or antigens missing in the red blood cells.

Blood groups are usually an individual's combination of antigens on the surface of RBCs, typically of the ABO blood group system and the RH blood group system.

Moreover, key players in the industry introduce innovative technologies that would propel this market growth. For instance, in May 2024, Thermo Fisher Scientific, introduced the Applied Biosystems Axiom BloodGenomiX Array and Software, a first-of-its-kind solution for more precise blood genotyping in clinical research.

The new array covers more than 40 genes and 260 antigens across 38 blood group systems in a single, high-throughput assay. It also detects tissue (HLA) and platelet (HPA) types. Validation studies have demonstrated its accuracy, with a concordance rate of 99.89% with participants' blood group antigen types.

In addition, government initiatives and awareness camps are propelling this segment's growth. As per the Hindu Business Line news in June 2022, the Centre calls for setting up blood group testing camps at all health centers on World Blood Donor Day. Centre calls for setting up blood group testing camps at all health centers on World Blood Donor Day.

Also, in June 2022, in Tamil Nadu, the Directorate of Public Health and Preventive Medicine launched the "Know Your Blood Group" campaign in all PHCs in the state.

Geographical Analysis

North America accounted for approximately 45.4% of the global blood group typing market share

North America region is expected to hold the largest market share over the forecast period. An increase in the number of road accidents and the rising prevalence of chronic diseases are the major factors driving the growth of the market.

In this region, advanced healthcare structure, government awareness programs, and partnerships and collaborations would drive this market growth. For instance, in January 2024, Mayor Muriel Bowser and the District of Columbia Fire and EMS Department announced the Whole Blood Program, an initiative designed to support and train paramedics in performing pre-hospital blood transfusions in partnership with the American Red Cross.

The Whole Blood Program is designed to increase survival rates and clinical outcomes for patients suffering from traumatic injuries, hemorrhagic shock, or severe bleeding by decreasing the amount of time it takes to replace lost blood.

Furthermore, there is an increasing demand for blood transfusion in the United States driving the market growth. According to U.S. blood supply facts in 2024, every 2 seconds someone in the U.S. needs blood and or platelets. Approximately 29,000 units of red blood cells are needed every day in the U. S. Nearly 5,000 units of platelets and 6.500 units of plasma are needed daily in the U.S.

Nearly 16 million blood components are transfused each year in the U.S. Sickle cell disease affects 90,000 to 100,000 people in the U.S. About 1,000 babies are born with the disease each year. Sickle cell patients can require blood transfusions throughout their lives.

Market Segmentation

By Product

• Consumables
• Instruments
• Services

By Technique

• PCR-based Techniques
  • Allele-specific PCR
  • Real-time PCR
• Assay-based Techniques
• Microarray-based Techniques
• Massively Parallel Sequencing

By Test Type

• ABO Blood Tests
• Antigen Typing
• Antibody Screening
• HLA Typing
• Cross Matching Tests

By End User

• Hospitals
• Blood Banks
• Clinical Laboratories
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the blood group typing market include Bio-Rad Laboratories, Inc., Grifols, Thermo Fisher Scientific Inc., Agena Bioscience, Inc., Bag Diagnostics, Lorne Laboratories Limited, Tulip Diagnostics, DIALAB GmbH, Rapid Labs Limited, and Immucor, Inc, among others.

Key Developments

• In May 2023, Bio-Rad Laboratories, Inc. announced the launch of the IH-500TM NEXT System, a fully automated system for ID cards. The IH-500 NEXT System not only reduces instrument downtime and increases laboratory productivity, but also provides the flexibility and freedom to use high-performing Bio-Rad Reagent Red Blood Cells (RBCs), as well as the lab's RBCs or third-party Reagent RBCs.
• In March 2022, Quotient Limited announced the receipt of the CE mark for the extended immunohematology microarray. The CE marking confirms the extended IH microarray meets the requirements of the European Medical Devices directive. The Company's MosaiQ platform offers an all-in-one, fully automated, high-performance solution in blood-testing laboratories and other settings.
• In September 2022, Scientists from NHS Blood and Transplant (NHSBT) and the University of Bristol discovered a new blood group system, called Er, solving a 30-year-old mystery. The team investigated three known blood group antigens - molecules on the surface of red blood cells that can trigger an attack by the immune system - which did not fit into any known blood group system.

Why Purchase the Report?

• To visualize the global blood group typing market segmentation based on product, technique, test type, end-user, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of global blood group typing market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in excel consisting of key products of all the major players.

The global blood group typing market report would provide approximately 70 tables, 68 figures, and 183 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product
• 3.2. Snippet by Technique
• 3.3. Snippet by Test Type
• 3.4. Snippet by End-User
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Number of Road Accidents, Emergencies, & Trauma Cases Necessitating Blood Transfusions
    • 4.1.1.2. Increasing Demand for Blood Group Typing in Prenatal Testing
    • 4.1.1.3. Rising Number of Blood Donations
  • 4.1.2. Restraints
    • 4.1.2.1. The High Cost of Blood Group Typing Products
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Unmet Needs
• 5.6. PESTEL Analysis
• 5.7. Patent Analysis
• 5.8. SWOT Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID
  • 6.1.2. Scenario During COVID
  • 6.1.3. Scenario Post COVID
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Product

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 7.1.2. Market Attractiveness Index, By Product
• 7.2. Consumables *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Instruments
• 7.4. Services

8. By Technique

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
  • 8.1.2. Market Attractiveness Index, By Technique
• 8.2. PCR-based Techniques *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Allele-specific PCR
• 8.4. Real-time PCR
• 8.5. Assay-based Techniques
• 8.6. Microarray-based Techniques
• 8.7. Massively Parallel Sequencing

9. By Test Type

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
  • 9.1.2. Market Attractiveness Index, By Test Type
• 9.2. ABO Blood Tests *
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Antigen Typing
• 9.4. Antibody Screening
• 9.5. HLA Typing
• 9.6. Cross Matching Tests

10. By End-User

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.1.2. Market Attractiveness Index, By End-User
• 10.2. Hospitals *
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Ambulatory Surgical Centers
• 10.4. Blood Banks
• 10.5. Clinical Laboratories
• 10.6. Others

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
  • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
  • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.7.1. U.S.
    • 11.2.7.2. Canada
    • 11.2.7.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
  • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.7.1. Germany
    • 11.3.7.2. UK
    • 11.3.7.3. France
    • 11.3.7.4. Italy
    • 11.3.7.5. Spain
    • 11.3.7.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
  • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
  • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.4.7.1. Brazil
    • 11.4.7.2. Argentina
    • 11.4.7.3. Rest of South America
• 11.5. Asia-Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
  • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.7.1. China
    • 11.5.7.2. India
    • 11.5.7.3. Japan
    • 11.5.7.4. South Korea
    • 11.5.7.5. Rest of Asia-Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
  • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
  • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Market Positioning/Share Analysis
• 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

• 13.1. Bio-Rad Laboratories, Inc *
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio & Description
  • 13.1.3. Financial Overview
  • 13.1.4. Key Developments
• 13.2. Grifols
• 13.3. Thermo Fisher Scientific Inc
• 13.4. Agena Bioscience, Inc
• 13.5. Bag Diagnostics
• 13.6. Lorne Laboratories Limited
• 13.7. Tulip Diagnostics
• 13.8. DIALAB GmbH
• 13.9. Rapid Labs Limited
• 13.10. Immucor, Inc

LIST NOT EXHAUSTIVE

14. Appendix

• 14.1. About Us and Services
• 14.2. Contact Us